Nanotechnology has been extensively explored in the past decade to develop a myriad of functional nanostructures to facilitate the delivery of therapeutic and imaging agents for various medical applications. Liposomes and polymeric nanoparticles represent two primary delivery vehicles that are currently under investigation. While many advantages of these two particle platforms have been disclosed, some intrinsic limitations remain to limit their applications at certain extent. Recently, a new type of nanoparticle platform, named lipidÀpolymer hybrid nanoparticle, has been developed that combines the positive attributes of both liposomes and polymeric nanoparticles while excluding some of their shortages. This new nanoparticle consists of a hydrophobic polymeric core, a lipid shell surrounding the polymeric core, and a hydrophilic polymer stealth layer outside the lipid shell. In this review, we¯rst introduce the synthesis and surface functionalization techniques of the lipidÀpolymer hybrid nanoparticle, followed by a review of typical characterization of the particles. We then summarize the current and potential medical applications of this new nanoparticle as a delivery vehicle of therapeutic and imaging agents. Finally we highlight some challenges faced in further developing this robust delivery platform.
Introduction
The development of highly selective and e®ective nanoparticles for drug delivery has brought new hope for the treatment of various notorious diseases such as cancers, cardiovascular diseases, diabetes, bacterial infections, and so on. 1À4 As a delivery vehicle, nanoparticles with a size range of 10À150 nm have demonstrated many advantages compared with the conventional approaches to the uses of drugs. 5À10 For example, therapeutic nanoparticles can improve the solubility of poorly water-soluble drugs, prolong the half-life of drugs in the systemic circulation by reducing immunogenicity, release drugs at a sustained rate and thus lower the frequency of administration, deliver drugs in a targeted manner to minimize systemic side e®ects, and deliver two or more drugs simultaneously for combination therapy to generate synergistic e®ects. As a result, a myriad of nanoparticle platforms have been designed for drug delivery applications. Some nanoparticle-based drug delivery products have been approved for clinical use. Numerous other ensuing products are currently under clinical testing or entering the pipeline. 11, 12 Among these clinical or pre-clinical products, liposomes and biodegradable polymeric nanoparticles represent the two most successful classes of drug delivery nanocarriers.
Liposomes are spherical lipid vesicles with a bilayer membrane structure consisting of amphiphilic lipid molecules. 13 Liposomes have been widely studied and used to deliver both hydrophilic and hydrophobic drugs in the past decades. 7, 14 Doxil was the¯rst liposome drug formulation approved by the Food and Drug Administration (FDA) for the treatment of AIDS associated with Kaposi's sarcoma in 1995. 15, 16 Other liposomal drug formulations that are also commercially available include DaunoXome (daunorubicin liposomes), DepotDur (morphine liposomes), Visudyne (vertepor¯n liposomes), DepoCyt (cytarabine in liposomes) and Ambisome (amphotericine B liposomes). 12, 17, 18 The bene¯ts of liposomal formulations include ability to carry hydrophilic drugs inside the aqueous vesicles and to carry hydrophobic drugs within the lipid bilayer membranes, high biocompatibility that provides perfect shield to protect drugs from external environment, and easy surface modi¯cation with other molecules such as polyethylene glycol (PEG) and targeting ligands to achieve prolonged systemic circulation lifetime and targeted drug delivery, respectively. However, the applications of liposomes are typically limited by some unfavorable features such as relatively complicated fabrication steps associated with liposome preparation and puri¯cation, low loading e±ciency for hydrophobic drugs, burst release kinetics of encapsulated drugs, and instability during storage leading to short shelf-time.
On the other hand, biodegradable polymeric nanoparticles have shown great therapeutic potential as a drug delivery nanocarrier.
19À24 Biodegradable polymers such as poly(D, L-lactic-co-glycolic acid) (PLGA) and poly("-caprolactone) (PCL) have been used in several FDA-approved therapeutic products. Their co-polymers with PEG are commonly used to form coreÀshell structured nanoparticles to encapsulate a variety of therapeutic agents.
25À28 These polymeric nanoparticles can carry hydrophobic drugs with a higher loading capacity than liposomes. Drug release from polymeric nanoparticles is usually dominated by polymer degradation and drug di®usion, which can be controlled by choosing proper polymers with desirable degradation rates and binding a±nity with the encapsulated drugs. Moreover, polymeric nanoparticles can be prepared by self-assembly of the block copolymers through a simple nanoprecipitation method, which allows cost-e®ective largescale fabrication of the particles. Despite all these appealing features, polymeric nanoparticles have not gained as much success as liposomes, presumably due to their moderate circulation lifetime and potential biocompatibility issues.
Recently, e®orts have been made to combine the positive attributes of both liposomes and polymeric nanoparticles into a single delivery system, called lipidÀpolymer hybrid nanoparticles. 29À35 This type of nanoparticles is typically comprised of three distinct functional components: (i) a hydrophobic polymeric core where poorly water-soluble drugs are incorporated with high loading yields; (ii) a lipid layer surrounding the core that acts as a highly biocompatible shell and as a molecular fence to promote drug retention inside the polymeric core; and (iii) a hydrophilic polymer stealth layer outside the lipid shell to enhance nanoparticle stability and systemic circulation lifetime. The polymeric core and the lipid shell are associated through hydrophobic interactions, van der Waals forces, electrostatic interactions or other non-covalent forces. The hydrophilic polymer stealth layer is often conjugated to the lipid shell through covalent bonds. These lipidÀpolymer hybrid nanoparticles have been demonstrated to include the unique advantages of both liposomes and polymeric nanoparticles while excluding some of their intrinsic limitations, thereby holding great promise as a delivery vehicle for various medical applications.
In this review article, we will¯rst introduce the synthesis methods of the lipidÀpolymer hybrid nanoparticles and their surface functionalization, followed by a review of the physicochemical and biomedical characterization of the nanoparticles. We will then summarize the current and potential medical applications of this new class of nanoparticles as a delivery vehicle of therapeutic and imaging agents. Finally we will highlight some challenges faced in further developing this robust delivery platform.
Synthesis of Lipid { Polymer Hybrid Nanoparticles
In general, lipidÀpolymer hybrid nanoparticles can be synthesized through two distinct approaches. As illustrated in Fig. 1 , one approach involves a twostep process in which the polymer core and lipid shell are prepared separately and then merged together; the other approach involves a single-step process, in which the hybrid nanoparticles are prepared through a one-pot nanoprecipitation and self-assembly method. For biomedical applications, the surface of the resulting lipidÀpolymer hybrid nanoparticles are usually further functionalized with targeting ligands for cell-or tissue-speci¯c delivery of the payloads.
Two-step synthesis approach
The two-step synthesis approach is typically used to prepare lipidÀpolymer hybrid nanoparticles with a lipid bilayer or multilayer shell. In this approach, the polymer core is formed through an emulsion method, 34 high-pressure homogenization method, 30 or nanoprecipitation method. 32 Liposome is prepared through a sonication method or extrusion method. 13 Then the polymer cores are mixed with the preformed liposomes at desirable molar ratios to prepare lipidÀpolymer hybrid nanoparticles by needle extrusion, high-pressure homogenization, or simply vortexing.
Several methods can be used to synthesize the polymer core of the hybrid nanoparticles depending on the hydrophobicity of the payloads and the needed size of the core. If the payload is miscible with the polymer in an organic solvent or the payload is covalently conjugated to the polymer chain, a single emulsion method is usually applied to prepare the payload-encapsulated polymer core. 36, 37 Brie°y, the payloads and the polymers are dissolved in a water immiscible organic solvent such as chloroform. Emulsion will be formed by adding the polymer solution into an aqueous solution that contains proper emulsi¯er, followed by high-speed homogenization. If the payloads are hydrophilic and cannot be dissolved into the organic solvent, a water-in-oil-inwater (w/o/w) double emulsion method is needed to prepare the polymer core. 38, 39 Brie°y, a water-in-oil (w/o) emulsion is formed by adding a payloadcontaining aqueous solution into a polymer-containing organic solvent. The resulting w/o emulsion is subsequently added into a second aqueous solution to form w/o/w double emulsion. The double emulsion is then hardened in an aqueous solution by evaporating the organic solvent. Generally, the emulsion method involves multiple steps in preparation and highenergy homogenization and results in large polymer particles with high polydispersity index.
High-pressure homogenization represents another method to prepare polymer core by using very high pressure to break polymer solutions or melted polymers into small droplets as they pass through a very narrow nozzle. 40 The obtained sub-micronsized droplets are subsequently hardened by spray drying or simply cooling down to room temperature. This method is simple and easy to control, however it has high demands on equipment and the resulting polymer particles are typically hundreds of nm in diameter.
In contrast, nanoprecipitation method is widely used to prepare sub-100 nm polymer particles. 19, 41, 42 This method involves the use of two miscible solvents; one is a good solvent of the polymer and the other one is a poor solvent of the polymer. The polymer is¯rst dissolved in the good solvent and then added to the poor solvent. As the good solvent di®uses into the poor solvent, the polymer will spontaneously precipitate out to form tiny particles. The mixing of the two solvents can happen through dropwise addition, stirring or sonication. Polymer concentration, volume ratio of the two solvents, and mixing rate can be tuned to control the size and polydispersity of the particles.
Once the polymer particles are prepared, they can be mixed with preformed lipid¯lms or liposomes to form lipidÀpolymer hybrid nanoparticles. The lipid components are usually dissolved in an organic solvent such as chloroform. 43 A thin lipid¯lm is formed by evaporating the organic solvent, to which an aqueous solution is added to rehydrate the lipids. The polymer particles can be added together with the aqueous solution to rehydrate the lipid¯lms or mixed with liposomes after they are prepared. Nevertheless, upon mixing through high-pressure homogenization, high-speed vortexing, or extrusion, the lipid¯lms or liposomes fuse on the surface of polymer core resulting in the formation of lipidÀpolymer hybrid nanoparticles. When the concentrations of both lipids and polymer core are properly controlled, a lipid bilayer will form on the surface of the polymer core due to noncovalent interactions. For example, cationic lipids can form a bilayer on carboxylic-acid-terminated PLGA polymer core through electrostatic attractions. When extra lipids are present in the mixture, a multilayer of lipids will form on the polymer core, resulting in an irregular lipid shell. 35 
One-step synthesis approach
The one-step synthesis approach is typically used to prepare lipidÀpolymer hybrid nanoparticles with a lipid monolayer shell. In this approach, 32 free polymers and hydrophobic drugs are dissolved in a water miscible organic solvent such as acetonitrile, while lipids and lipidÀPEG conjugates are dissolved in an aqueous solution. In order to facilitate the solubilization of phospholipids in the aqueous solutions, a small amount of water miscible organic solvent can be added in the aqueous solution. The polymer solution is then added into the lipid aqueous solution dropwise. The organic solvent di®uses into the aqueous solution quickly, leaving polymer to precipitate into nanoparticles. The lipids and lipidÀPEG will self-assemble on the surface of polymer nanoparticles through hydrophobic interactions to reduce the system's free energy. The hydrophobic tail of lipids will stick to the hydrophobic polymer core and the hydrophilic head group of lipids will extend into the external aqueous environment. The lipidÀPEG conjugate will also participate into the self-assembly process with its lipid moiety inserting into the lipid monolayer and its PEG moiety facing outside of the lipid monolayer to form a stabilizing and stealth corona of the nanoparticles. An elevated temperature above lipid phase transition temperature may help the selfassembly of lipids and lipidÀPEG conjugates. As the self-assembled lipid monolayer forms due to hydrophobic interactions, a hydrophobic polymer such as PLGA and PCL should be used. This onestep self-assembly approach represents a cost-e®ec-tive, scalable, and predictable formulation strategy of lipidÀpolymer hybrid nanoparticles.
Surface functionalization of lipidÀpolymer hybrid nanoparticles
The PEG layer is essential to maintain the stability of the hybrid nanoparticles both in vitro by reducing nanoparticle aggregation and in vivo by allowing the particles to evade recognition by the reticuloendothelial system (RES) and other immune cells. Moreover, the PEG molecules also provide functional groups for further modi¯cation of the hybrid nanoparticles with targeting ligands for cell-or tissuespeci¯c drug delivery. Many targeting ligands have been disclosed by researchers including monoclonal antibodies, antibody fragments, aptamers, peptides, and small molecules such as folic acid. 44 In principle all these targeting ligands can be conjugated with the lipidÀpolymer hybrid nanoparticles to enhance delivery e±ciency (see Fig. 2 ). For example, Chan et al. have demonstrated the conjugation of a peptide (sequence: KLWVLPK) to the surface of lipidÀpolymer hybrid nanoparticles for spatio-temporal delivery of nanoparticles to injured vasculature. 33 The peptide was covalently conjugated to PEG molecules through maleimide-thiol coupling. It was found that the targeted hybrid nanoparticles inhibited human aortic smooth muscle cell proliferation in vitro and showed greater in vivo vascular retention during percutaneous angioplasty over nontargeted controls.
In addition, Hu et al. have recently reported the use of half-antibody functionalized lipidÀpolymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. 45 Wang et al. have conjugated A10 RNA aptamer, a ligand with high speci¯city and a±nity to prostate-speci¯c membrane antigen (PSMA), to the hybrid nanoparticles through 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) coupling reaction. 46 The resulting targeted hybrid nanoparticles achieved high selectivity to prostate cancer cells.
Another recent e®ort made by Liu et al. has demonstrated that with folate incorporated on the shell, the hybrid nanoparticles had improved targeting ability and cellular toxicity against breast cancer cells but not¯broblast cells. 31 Although further in vivo tests in animal models are required to validate the therapeutic potential of these targeted hybrid nanoparticles, the functional PEG layer provides tremendous°exibility for formulation design and modi¯cation of the hybrid nanoparticles.
Characterization of Lipid { Polymer
Hybrid Nanoparticles
Physicochemical properties
Nanoparticle size, surface zeta potential and morphology are key physicochemical properties that determine the in vivo pro¯les of the hybrid nanoparticles.
Particle size is one of the most critical factors to determine systemic circulation lifetime of the nanoparticles and their ability to passively accumulate in tumor tissues. It has been well-documented that nanoparticles with a size range of 10À150 nm are highly bene¯cial and favorable for systemic drug delivery. 47À49 The hydrodynamic size and size distribution of nanoparticles can be measured by dynamic light scattering (DLS). This method is fast and straightforward without involving additional sample treatments prior to the measurement. However, this technique does not always provide the actual physical size of the particles, especially when the particles are not uniformly spherical and have large polydispersity. Scanning electron microscopy (SEM) or transmission electron microscopy (TEM) will then be used to measure the physical dimension and structure of the particles.
Valencia et al. have studied several factors that a®ect particle size and polydispersity of the lipidÀpolymer hybrid nanoparticles. 50 Rapid mixing of lipid and polymer solutions results in more homogeneous nanoparticles compared to slow mixing. In addition, polymer concentration and polymer inherent viscosity also a®ect particle size. Higher polymer concentration leads to larger particle size, while polymer with higher inherent viscosity produces smaller particles.
Surface zeta potential is a measure of electrokinetic potential between particle surface and the bulk solution. 47 It represents the surface electrical charges of the nanoparticles and is a critical factor to determine both in vitro and in vivo stability of the particles. The zeta potential of nanoparticles can be measured using DLS by applying an oscillating electric¯eld and monitoring the movement of the particles as they are attracted or repulsed by the electric¯eld. For lipidÀpolymer hybrid nanoparticles, their surface zeta potential can be tuned by changing the end functional groups of the PEG molecules. For example, by utilizing ÀCOOH, ÀCH 3 , and ÀNH 2 end groups, the zeta potential of the hybrid nanoparticles showed negative, nearly neutral and positive surface charges, respectively. 51 Usually higher absolute zeta potential values lead to more stable nanoparticles in vitro as the surface charges repel particles from contacting one another. However, immunocompatibility study has shown that the hybrid nanoparticles with methoxyl surface groups induced the lowest complement activation, while the nanoparticles with amine surface groups induced the highest activation. 51 Therefore an optimal surface charge needs to be selected to balance in vitro stability and in vivo immunocompatibility of the hybrid nanoparticles.
The morphology and the coreÀshell structure of the hybrid nanoparticles can be measured by electron microscopy. The nanoparticles are typically dried or xed on a silicon wafer substrate for scanning electron microscopy (SEM) imaging, from which an actual physical size and size distribution can be obtained. With high resolution SEM, surface morphology of hybrid nanoparticles may also be observed. 31 The internal coreÀshell structure is typically measured by transmission electron microscopy (TEM), in which negative stains are often used to increase electron contrast in order to highlight speci¯c particle components. For instance, Thevenot et al. was able to see a lipid multilayer absorbing outside a polymer core using TEM with sodium silico tungstate for negative staining. 35, 52 Uranyl acetate is another common negative stain that enhances the electron density of lipids and lipidÀPEG conjugates. Zhang et al. observed a dim ring with less than 5 nm thickness surrounding the polymer core in their lipidÀpolymer hybrid nanoparticles prepared through a one-step self-assembly process. 32 Cryo-electron microscopy technique (CEM) is another powerful tool to study the coreÀshell structure of the hybrid nanoparticles, in which the samples are imaged under extremely cold temperature (usually liquid nitrogen temperature). Using this technique, Bershteyn et al. was able to observe the striking e®ects of lipid quantity and composition on the structure of lipid shell. 53 
In vitro stability
Nanoparticle stability in PBS solution and serum is critical for their utility as a drug delivery vehicle in vivo. High surface area to volume ratio associated with nanoparticles makes them prone to aggregate in solution. Nanoparticle stability can be evaluated by monitoring their changes of size, polydispersity, and surface zeta potential at di®erent in vitro conditions. Several factors will determine the in vitro stability of the lipidÀpolymer hybrid nanoparticles, including nanoparticle concentration, surface charge density, and surface repulsive layer.
When nanoparticle concentration is too high, the chance of particles running to each other signi¯-cantly increased. This will increase the possibility of particle aggregation due to particleÀparticle interactions through van de Waals forces. 54 Hence, the total volume fraction of nanoparticles in the solution needs to be controlled.
Surface charge density is directly related to the in vitro stability of drug delivery nanoparticles. For the lipidÀpolymer hybrid nanoparticles, their surface charge density is determined by the lipid surface coverage and lipid/lipidÀPEG ratio. It has been shown that nearly complete surface coverage by lipids is essential to avoid nanoparticle aggregation in PBS bu®er. In addition, the lipid/lipidÀPEG molar ratio also plays a signi¯cant role in stabilizing the hybrid nanoparticles, especially when the PEG molecules are terminated with charged carboxylic acid or amine groups. 50 As mentioned earlier, surface charge density is measured as surface zeta potential. Typically nanoparticles with a surface zeta potential value larger than 30 mV or smaller than À30 mV are considered as a stable formulation for in vitro storage.
A surface repulsive layer that provides steric repulsive forces to keep particles away from one another is needed when concentration and surface charge density are not su±cient to stabilize the nanoparticles. Steric repulsive force in hybrid nanoparticles is provided by PEG molecules on the nanoparticle surface. Both PEG chain length and lipid/lipidÀPEG molar ratio have signi¯cant impact on nanoparticle stability. Thevenot et al. studied the e®ect of PEG chain lengths (n ¼ 16, 45, 113) on the stability of their hybrid nanoparticles with a lipid bilayer shell, called LipoParticle, in PBS solution. 35 It was found that 10 mol% of lipidÀPEG (n ¼ 16) formed a lipid/lipidÀPEG shell with a thickness of about 2.4 nm, which was not su±cient to provide any improvement in particle stability. In contrast, by replacing the PEG (n ¼ 16) with PEG (n ¼ 131), the shell thickness increased to 9.8 nm and the nanoparticles remained stable with small size and narrow size distribution. As another example, Chan et al. found the most stable formulation of their hybrid nanoparticles with a lipid monolayer shell was to be 15 wt% lipid/polymer mass ratio and 7.5:2.5 lipid/lipidÀPEG molar ratio. 29 Besides testing nanoparticle in vitro stability in water and PBS solution, some studies were performed in serum or plasma, which would provide valuable prediction of particle behavior in vivo. Unstable nanoparticles, once mixed with whole serum, quickly adsorb serum proteins and form aggregates resulting in large particle size and broad size distribution. While some researchers have performed 100% serum stability studies for other types of nanoparticles, 55, 56 most studies are carried out using diluted serum, 10% serum in particular. This is simply because whole serum contains many proteins and protein aggregates, which interfere with the DLS measurement of nanoparticle size. Other techniques are needed to evaluate particle stability in 100% serum or whole blood.
Drug loading and release
The lipidÀpolymer hybrid nanoparticles represent a robust drug delivery platform to carry hydrophobic drugs with high loading yields and to control their release rates. The hydrophobic polymer core can contain large amount of hydrophobic drugs, which can be either physically encapsulated inside the polymer core or chemically linked to the polymer chains. The lipid shell is expected to (a) prevent small drug molecules from freely di®using out of the polymer core, thereby improving drug loading yield; and (b) reduce water penetration rate into the polymer core, thereby decreasing the rate of polymer degradation and slowing down drug release from the particles. Zhang et al. have demonstrated that the addition of a lipid monolayer shell signi¯cantly improved the encapsulation and loading yields of docetaxel, a hydrophobic anticancer drug, as compared to the corresponding polymeric nanoparticles without a lipid shell. 32 There are several factors that a®ect drug release pro¯le of the hybrid nanoparticles, including drugÀpolymer interaction, drug solubility, polymer degradation rate, and particle size. For physically encapsulated drugs, they are released from the hybrid nanoparticles through drug di®usion and polymer erosion. For chemically conjugated drugs, their release is determined by the hydrolysis of the linkers between the drugs and polymer chains and subsequent drug di®usion. 57 Drug release study is usually performed through a dialysis method. Brie°y, a dialysis cassette containing drug-loaded nanoparticles is placed in a large volume release medium at 37 C with moderate agitation. The drug molecules will continuously di®use out of the nanoparticles and leach into the release medium. The released drugs or the drugs remained inside the nanoparticles are collected at a series of time points for quanti¯cation using analytical tools such as high performance liquid chromatography (HPLC) and mass spectrometer. 58, 59 3.4. Cellular uptake and cytotoxicity Cellular uptake and cytotoxicity are typical in vitro assays to assess speci¯city and e®ectiveness of drugloaded nanoparticles against target cells prior to in vivo evaluations. Cellular uptake of nanoparticles is examined by tagging the nanoparticles with proper°uorescent probes such as°uorescence isothiocyanate (FITC) followed by incubating these°u orescence-tagged nanoparticles with cells. After removing the excess particles, the cells will be imaged to visualize particle internalization and distribution using°uorescence microscopy such as a confocal laser scanning microscope (CLSM). 60 The mechanisms of in vitro cellular uptake of nanoparticles are believed to be endocytosis or nonspeci¯c engulfment. To facilitate cellular uptake of the hybrid nanoparticles, targeting ligands are typically conjugated to the surface of the nanoparticles to activate the receptor-mediated endocytosis. As described in Sec. 2.3, a variety of targeting ligands have been used to promote binding specicity and cellular uptake of the hybrid nanoparticles. As one example, by conjugating a monoclonal half-antibody onto the hybrid nanoparticle surface, Hu et al. have demonstrated that speci¯c and intensive cellular uptake of the particles by pancreatic cancer cells occurred within only 30-minute incubation. 45 Cellular cytotoxicity analysis is usually performed by incubating drug-loaded nanoparticles with cells for a period of time. Then the cells will be washed and supplemented with fresh media. Following 72 hours of additional culture, cell viability will be assessed with appropriate assays such as the well-known MTT assay and ATP assay. It has been well-documented that the cytotoxicity of the drugs encapsulated inside the hybrid nanoparticles was well-preserved. In fact, as compared to free drugs, the nanoparticles signi¯cantly enhanced the toxicity of the drugs by delivering a bolus dose of drugs to individual diseased cells after the particles are internalized by the cells. 
In vivo evaluation
One of the major issues with drug delivery nanoparticles is their limited circulation lifetime in the blood stream. Once the nanoparticles enter the circulation system, plasma proteins can quickly adsorb onto the surface of the particles and then promote opsonization, resulting in rapid clearance of the particles from blood by the mononuclear phagocyte system (MPS) in the liver and spleen. 63 It has been disclosed that particle size, surface charge, PEG modi¯cation and targeting functionality are all important factors to determine the in vivo behavior of the drug delivery nanoparticles. 25, 64, 65 It is commonly accepted that pegylated nanoparticles with a size range of 10À150 nm and slightly negative surface charge are able to stay in the systemic circulation systems for hours and preferentially extravasate into the tumor tissues through passive di®usion and active targeting e®ects.
47À49 Because of the unique coreÀshell structure and°exibility in controlling their size, surface charge, and surface functionalization, lipidÀpolymer hybrid nanoparticles hold great promise to achieve desirable in vivo pharmacokinetic properties. Sengupta et al. have successfully demonstrated the excellent pharmacokinetics and therapeutic e±cacy of their lipidÀpolymer hybrid nanoparticles, called nanocell, to cure melanoma and Lewis lung carcinoma. 34 Overall, as a relatively new drug delivery platform, limited amount of in vivo data is available for the hybrid nanoparticles, although extensive in vivo studies are currently ongoing in di®erent research laboratories.
Targeted delivery represents another major interest of nanoparticle drug delivery research. A common method is to conjugate cell-or tissuespeci¯c ligands onto the surface of the nanoparticles to actively target the particles to sites of action. While some very promising results have been observed in cell culture experiments for the lipidÀpolymer hybrid nanoparticles, further in vivo studies are needed to evaluate their tissue targeting ability.
Applications of Lipid { Polymer Hybrid Nanoparticles

Therapeutics delivery
LipidÀpolymer hybrid nanoparticles can be formulated to e±ciently encapsulate and deliver a wide variety of therapeutic agents. These drugs can be loaded inside the nanoparticles alone or in a combination with two or more di®erent types of drugs. Hydrophobic drugs can be directly and physically entrapped in the polymer core during the nanoprecipitation process and lipophilic drugs can be incorporated into the lipid shell. To further control the release kinetics of the drugs, they can be covalently linked to the polymer chains. For single-drug delivery, a successful example was recently reported by Chan et al., in which a \nanoburr" system was designed to deliver paclitaxel for the treatment of injured vasculature. 33 The nanoburr contains a paclitaxel-conjugated PLA core and a lecithin/ DSPE-PEG shell, which is further modi¯ed by a basement membrane targeting peptide. The sub-100 nm lipidÀpolymer hybrid nanoparticles speci¯-cally accumulated in injured vasculature in a rat model and continuously released drugs over two weeks.
Moreover, the hybrid nanoparticles have shown great potential for combinatorial drug delivery. For example, Wang et al. have reported a targeted hybrid nanoparticle system to concurrently deliver chemotherapy and radiotherapy agents for the treatment of prostate cancer. 46 In their system, an anticancer drug, docetaxel, was¯rst encapsulated inside the polymer core during the nanoprecipitation process, and then a radioisotope, 111 In, was chelated onto the particle surface. The resulting dual-drug-loaded nanoparticles showed distinct release pro¯les for both drugs and enhanced killing of tumor cells. As another example, Sengupta et al. have designed a \nanocell" system to¯ght against tumor step by step. 34 The nanocell consists of a PLGA polymer core containing a chemotherapy drug (doxorubicin) and a lipid multilayer shell containing an anti-angiogenic agent (combretastatin). The resulting nanocell signi¯cantly improved tumor reduction and increased mouse survival rates as compared to the treatment with single drug or a mixture of the two drugs. The synergistic e®ect was achieved by temporal release of the two anti-cancer agents: the outer lipid shell¯rst released the anti-angiogenesis agent, causing a rapid vascular shutdown; the inner polymer core that has already been entrapped inside the tumor tissue then released the chemotherapy agent to further destroy the tumor cells. Very recently, a new approach has been reported by Aryal et al. to concurrently load both hydrophobic and hydrophilic drugs to the lipidÀpolymer hybrid nanoparticles based on a combinatorial drug conjugation method. 61 These nanoparticle-assisted combination therapies may provide a new paradigm for e®ective cancer treatment.
Imaging agent delivery
Besides delivering therapeutic agents, the lipidÀpolymer hybrid nanoparicle can also be used to deliver a variety of imaging agents such as iron oxide,°uorescent dyes, and quantum dots (QDs) by encapsulating them inside the polymer core. Moreover, Valencia et al. used QDs to replace the hydrophobic polymer to fabricate lipidÀQD hybrid nanoparticles by a fast mixing method within a micro°uidic device. 50 TEM images showed monodispersed lipidÀQD hybrid particles with an average size of 60 nm. The encapsulated QDs remained their°uorescence properties and exhibited high stability in solutions.
Conclusion and Future Prospective
LipidÀpolymer hybrid nanoparticles o®er numerous advantages as a drug delivery platform including simple fabrication process, tunable size and surface charge, high loading capacity of poorly water-soluble drugs, sustained and controllable release pro¯le of the drugs, high in vitro stability, and excellent in vivo properties. All of these features make the lipidÀpolymer hybrid nanoparticles an ideal drug delivery platform. Despite the great progress made on synthesis, characterization and applications of the hybrid nanoparticles, we call attention to a few key unmet challenges in further developing this new nanoparticle platform as a robust drug delivery system for medical applications.
First, optimizing the targeting ligand density on the nanoparticle surface is critical to achieve optimal therapeutic e±cacy. It is well-documented that the physicochemical properties of the hybrid nanoparticles such as particle size, surface charge, PEG chain density will a®ect their in vivo pharmacokinetics. Therefore the conjugation of targeting ligands on the one hand will improve the cell-or tissuespeci¯c targeting ability, but on the other hand may compromise the surface properties of the hybrid particles and thus negatively a®ect their pharmacokinetic properties. Many types of targeting ligands have been conjugated to improve the accumulation of the hybrid nanoparticles to the sites of action. It would be desirable to screen and optimize the ligand density through in vivo experiments.
Secondly, precise control of multiple drugs with di®erent hydrophobicity inside the same hybrid nanoparticles remains challenging. Although several attempts have been demonstrated to concurrently load dual drugs to the hybrid nanoparticles, the molar ratio of the two drugs and their loading yields are di±cult to be precisely controlled. This may potentially limit the synergistic e®ects among the drug combinations.
Lastly, large-scale fabrication of these hybrid nanoparticles has received little attention, which could become a key factor that determines the bench-to-bedside translation of these drug delivery vehicles. The simplicity of the synthesis process, especially the one-step self-assembly process, dramatically increases the likelihood of producing the lipidÀpolymer hybrid nanoparticles in a scalable and economical manner.
